You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRosiglitazone
Accession NumberDB00412  (APRD00403)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer’s disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.

Structure
Thumb
Synonyms
SynonymLanguageCode
(±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedioneNot AvailableWHO
(RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedionNot AvailableIUPAC
RosiglitazonGermanINN
RosiglitazonaSpanishINN
RosiglitazoneNot Available DCF, BAN
RosiglitazonumLatinINN
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Avandiatablet, film coated2 mgoralGlaxo Smith Kline Llc2011-05-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Avandiatablet, film coated4 mgoralGlaxo Smith Kline Llc2011-05-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Avandiatablet, film coated8 mgoralGlaxo Smith Kline Llc2011-05-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Avandiatablet, film coated4 mgoralPhysicians Total Care, Inc.2006-02-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Avandiatablet, film coated8 mgoralPhysicians Total Care, Inc.2001-05-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Avandiatablet, film coated2 mgoralPhysicians Total Care, Inc.2005-05-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Avandiatablet, film coated4 mgoralCardinal Health1999-05-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Avandiatablet, film coated8 mgoralCardinal Health1999-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Avandiatablet2 mgoralGlaxosmithkline IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Avandiatablet4 mgoralGlaxosmithkline IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Avandiatablet8 mgoralGlaxosmithkline IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International Brands
NameCompany
BlutabWerrick
DH-RosidiaHasan
DiabenElea
DiaglinexFarmindustria
GaudilCraveri
GliximinaDenver
NaidiHisun
RogelinTorrent
RoglitGedeon Richter
RomerolDrug International
RositDelta
RosixGarmisch
RossiniTrima
SensulinSquare
Sheng AoHengrui
Sheng MinShengJiTang Pharmaceutical
Brand mixtures
Brand NameIngredients
ArometRosiglitazone and Metformin
AvaglimRosiglitazone and Glimepiride
AvandametRosiglitazone and Metformin
AvandarylRosiglitazone and Glimepiride
AvglimRosiglitazone and Glimepiride
GlyrosRosiglitazone and Glimepiride
Grexa PlusRosiglitazone and Glimepiride
MetiglitRosiglitazone and Metformin
Oramet PlusRosiglitazone and Metformin
Rogelin 2MF/4MFRosiglitazone and Metformin
RoglimRosiglitazone and Glimepiride
RosiglimRosiglitazone and Glimepiride
RosimetRosiglitazone and Metformin
RotaminRosiglitazone and Metformin
Salts
Name/CASStructureProperties
Rosiglitazone Maleate
155141-29-0
Thumb
  • InChI Key: SUFUKZSWUHZXAV-BTJKTKAUNA-N
  • Monoisotopic Mass: 473.125670795
  • Average Mass: 473.499
DBSALT000153
CategoriesNot Available
CAS number122320-73-4
WeightAverage: 357.427
Monoisotopic: 357.114712179
Chemical FormulaC18H19N3O3S
InChI KeyYASAKCUCGLMORW-UHFFFAOYNA-N
InChI
InChI=1/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
IUPAC Name
5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione
SMILES
CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentPhenol ethers
Alternative Parents
Substituents
  • Dialkylarylamine
  • Phenol ether
  • Thiazolidinedione
  • Aminopyridine
  • Alkyl aryl ether
  • Imidolactam
  • Pyridine
  • Heteroaromatic compound
  • Thiazolidine
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Thioether
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationRosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
PharmacodynamicsWhen rosiglitazone is used as monotherapy, it is associated with increases in total cholesterol, LDL, and HDL. It is also associated with decreases in free fatty acids. Increases in LDL occurred primarily during the first 1 to 2 months of therapy with AVANDIA and LDL levels remained elevated above baseline throughout the trials. In contrast, HDL continued to rise over time. As a result, the LDL/HDL ratio peaked after 2 months of therapy and then appeared to decrease over time.
Mechanism of actionRosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, rosiglitazone enhances tissue sensitivity to insulin.
AbsorptionThe absolute bioavailability of rosiglitazone is 99%. Peak plasma concentrations are observed about 1 hour after dosing. Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours). These changes are not likely to be clinically significant; therefore, rosiglitazone may be administered with or without food. Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range.
Volume of distribution
  • 17.6 L [oral volume of distribution Vss/F]
  • 13.5 L [population mean, pediatric patients]
Protein binding99.8% bound to plasma proteins, primarily albumin.
Metabolism

Hepatic. Rosiglitazone is extensively metabolized in the liver to inactive metabolites via N-demethylation, hydroxylation, and conjugation with sulfate and glucuronic acid. In vitro data have shown that Cytochrome (CYP) P450 isoenzyme 2C8 (CYP2C8) and to a minor extent CYP2C9 are involved in the hepatic metabolism of rosiglitazone.

SubstrateEnzymesProduct
Rosiglitazone
N-DesmethylrosiglitazoneDetails
Rosiglitazone
para-HydroxyrosiglitazoneDetails
Rosiglitazone
ortho-HydroxyrosiglitazoneDetails
Rosiglitazone
Not Available
N-Despyridinyl rosiglitazoneDetails
N-Desmethylrosiglitazone
Not Available
N-Desmethyl-ortho-hydroxy rosiglitazoneDetails
ortho-Hydroxyrosiglitazone
Not Available
N-Desmethyl-ortho-hydroxy rosiglitazoneDetails
N-Desmethylrosiglitazone
Not Available
N-Desmethyl-para-hydroxy rosiglitazoneDetails
para-Hydroxyrosiglitazone
Not Available
N-Desmethyl-para-hydroxy rosiglitazoneDetails
N-Desmethyl-ortho-hydroxy rosiglitazone
Not Available
N-Desmethyl-ortho-O-sulfate rosiglitazoneDetails
ortho-Hydroxyrosiglitazone
Not Available
ortho-O-Glucuronide rosiglitazoneDetails
ortho-Hydroxyrosiglitazone
Not Available
ortho-O-Sulfate rosiglitazoneDetails
N-Desmethylrosiglitazone
Not Available
N-Desmethyl glucuronide rosiglitazoneDetails
para-Hydroxyrosiglitazone
Not Available
para-O-Glucuronide rosiglitazoneDetails
para-Hydroxyrosiglitazone
Not Available
para-O-Sulfate rosiglitazoneDetails
N-Desmethyl-para-hydroxy rosiglitazone
Not Available
N-Desmethyl para-O-sulfate rosiglitazoneDetails
Rosiglitazone
Not Available
Phenoxyacetic acid derivative of rosiglitazoneDetails
Route of eliminationFollowing oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.
Half life3-4 hours (single oral dose, independent of dose)
Clearance
  • Oral clearance (CL) = 3.03 ± 0.87 L/hr [1 mg Fasting]
  • Oral CL = 2.89 ± 0.71 L/hr [2 mg Fasting]
  • Oral CL = 2.85 ± 0.69 L/hr [8 mg Fasting]
  • Oral CL = 2.97 ± 0.81 L/hr [8 mg Fed]
  • 3.15 L/hr [Population mean, Pediatric patients]
ToxicitySide effects include fluid retention, congestive heart failure (CHF), liver disease
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Rosiglitazone Metabolism PathwayDrug metabolismSMP00653
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9861
Blood Brain Barrier+0.8994
Caco-2 permeable-0.5451
P-glycoprotein substrateSubstrate0.6535
P-glycoprotein inhibitor INon-inhibitor0.5274
P-glycoprotein inhibitor IINon-inhibitor0.6289
Renal organic cation transporterNon-inhibitor0.5203
CYP450 2C9 substrateNon-substrate0.7418
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5744
CYP450 1A2 substrateInhibitor0.5391
CYP450 2C9 substrateInhibitor0.5783
CYP450 2D6 substrateNon-inhibitor0.846
CYP450 2C19 substrateInhibitor0.5884
CYP450 3A4 substrateNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7213
Ames testNon AMES toxic0.687
CarcinogenicityNon-carcinogens0.9465
BiodegradationNot ready biodegradable0.8635
Rat acute toxicity2.4515 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8055
hERG inhibition (predictor II)Non-inhibitor0.7768
Pharmacoeconomics
Manufacturers
  • Sb pharmco puerto rico inc
  • Glaxosmithkline
Packagers
Dosage forms
FormRouteStrength
Tabletoral2 mg
Tabletoral4 mg
Tabletoral8 mg
Tablet, film coatedoral2 mg
Tablet, film coatedoral4 mg
Tablet, film coatedoral8 mg
Prices
Unit descriptionCostUnit
Avandia 8 mg tablet8.69USD tablet
Avandia 4 mg tablet4.72USD tablet
Avandia 2 mg tablet3.22USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada13284521994-04-122011-04-12
Canada21438492000-04-252013-09-01
United States50029531994-09-172011-09-17
United States73583662000-10-192020-10-19
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point122-123 °CNot Available
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.038 mg/mLALOGPS
logP2.95ALOGPS
logP2.45ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)6.84ChemAxon
pKa (Strongest Basic)6.23ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area71.53 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity97.79 m3·mol-1ChemAxon
Polarizability37.8 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Manne Reddy, “Amorphous form of rosiglitazone maleate and process for preparation thereof.” U.S. Patent US20040242658, issued December 02, 2004.

US20040242658
General Reference
  1. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P: Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004 Jun;89(6):2728-35. Pubmed
  2. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006 Dec 7;355(23):2427-43. Epub 2006 Dec 4. Pubmed
External Links
ATC CodesA10BG02
AHFS Codes
  • 68:20.28
PDB EntriesNot Available
FDA labelDownload (86.2 KB)
MSDSDownload (30 KB)
Interactions
Drug Interactions
Drug
AvanafilCo-administration with avanafil resulted in an approximate 2.0% increase in AUC0-inf and 14% decrease in Cmax of rosiglitazone.
ColesevelamBile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione). Separate the dosing of bile acid sequestrants and thiazolidinediones by at least 2 hours. Monitor for reduced effects of the antidiabetic agents.
GemfibrozilIncreases the effect and toxicity of rosiglitazone/pioglitazone
KetoconazoleKetoconazole increases the effect of rosiglitazone
RifampicinRifampin reduces levels and efficacy of rosiglitazone
Somatropin recombinantSomatropin may antagonize the hypoglycemic effect of rosiglitazone. Monitor for changes in fasting and postprandial blood sugars.
TretinoinThe moderate CYP2C8 inhibitor, Rosiglitazone, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rosiglitazone is initiated, discontinued to dose changed.
Food InteractionsNot Available

Targets

1. Peroxisome proliferator-activated receptor gamma

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Peroxisome proliferator-activated receptor gamma P37231 Details

References:

  1. Su JL, Winegar DA, Wisely GB, Sigel CS, Hull-Ryde EA: Use of a PPAR gamma-specific monoclonal antibody to demonstrate thiazolidinediones induce PPAR gamma receptor expression in vitro. Hybridoma. 1999 Jun;18(3):273-80. Pubmed
  2. Rieusset J, Auwerx J, Vidal H: Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun. 1999 Nov;265(1):265-71. Pubmed
  3. Kameda N, Okuya S, Oka Y: [Rosiglitazone (BRL-49653)] Nippon Rinsho. 2000 Feb;58(2):401-4. Pubmed
  4. Johnson BA, Wilson EM, Li Y, Moller DE, Smith RG, Zhou G: Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. J Mol Biol. 2000 Apr 28;298(2):187-94. Pubmed
  5. Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen X, Vanbogelen R, Leff T: Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes. 2000 Apr;49(4):539-47. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Long-chain-fatty-acid--CoA ligase 4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Long-chain-fatty-acid--CoA ligase 4 O60488 Details

References:

  1. Askari B, Kanter JE, Sherrid AM, Golej DL, Bender AT, Liu J, Hsueh WA, Beavo JA, Coleman RA, Bornfeldt KE: Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophages. Diabetes. 2007 Apr;56(4):1143-52. Epub 2007 Jan 26. Pubmed

Enzymes

1. Cytochrome P450 2C8

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Prostaglandin G/H synthase 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Prostaglandin G/H synthase 1 P23219 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

4. Cytochrome P450 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 2A6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2A6 P11509 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 2C19

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

7. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Carriers

1. Serum albumin

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Serum albumin P02768 Details

References:

  1. FDA label

Transporters

1. Solute carrier organic anion transporter family member 1B1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 1B1 Q9Y6L6 Details

References:

  1. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, Tamai I: Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos. 2004 Mar;32(3):291-4. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on November 29, 2013 14:37